Literature DB >> 19490557

Valuing condition-specific health states using simulation contact lenses.

Carolyn Czoski-Murray1, Jill Carlton, John Brazier, Tracey Young, Natalie L Papo, Hyong Kwon Kang.   

Abstract

OBJECTIVE: This article reports on a study that used contact lenses to simulate the effects of a visual impairment caused by age-related macular degeneration (ARMD). The primary objective was to examine the feasibility of using this method of simulation. A secondary objective was to compare the results from this experiment with those obtained from ARMD patients (n = 209) using generic preference-based measures (Health Utilities Index 3 (HUI3) and EUROQOL 5 Dimensions (EQ-5D) and patient time trade-off (TTO).
METHODS: Utility values were elicited from healthy participants (n = 108) for three ARMD states simulated using contact lenses.
RESULTS: A significant relationship was found between visual acuity and TTO values elicited from our sample population (n = 108). It was stronger than that found for HUI3, EQ-5D, and own TTO values from patients (n = 209). Our sample values informed by the experience of simulation were found to be significantly different from values from patient TTO and generic preference-based measures obtained from patients for the same level of visual impairment. Sociodemographic characteristics did not significantly affect results, although baseline TTO utility values were positively associated with TTO values for simulated states. Nevertheless, the patient population was significantly older than the sample population.
CONCLUSIONS: ARMD has a major impact on our sample values TTO health state values. Differences across four visual health severity groups appear larger than those found for a generic preference-based measure and patient TTO values. For conditions that are difficult to describe and imagine, simulation methods may offer an additional tool when combined with usual methods of description for obtaining better informed general population preferences.

Entities:  

Mesh:

Year:  2009        PMID: 19490557     DOI: 10.1111/j.1524-4733.2009.00527.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  19 in total

1.  Seeing other perspectives: evaluating the use of virtual and augmented reality to simulate visual impairments (OpenVisSim).

Authors:  Pete R Jones; Tamás Somoskeöy; Hugo Chow-Wing-Bom; David P Crabb
Journal:  NPJ Digit Med       Date:  2020-03-10

2.  Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.

Authors:  David W Hutton; Joshua D Stein; Neil M Bressler; Lee M Jampol; David Browning; Adam R Glassman
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

3.  Cost-effectiveness of cataract surgery in Japan.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2011-06-22       Impact factor: 2.447

4.  Simulation of a central scotoma using contact lenses with an opaque centre.

Authors:  Essam S Almutleb; Arthur Bradley; Jason Jedlicka; Shirin E Hassan
Journal:  Ophthalmic Physiol Opt       Date:  2018-01       Impact factor: 3.117

5.  Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.

Authors:  Lindsay Claxton; Robert Hodgson; Matthew Taylor; Bill Malcolm; Ruth Pulikottil Jacob
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

6.  Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality.

Authors:  Thomas Butt; Michael D Crossland; Peter West; Shepley W Orr; Gary S Rubin
Journal:  Br J Ophthalmol       Date:  2014-10-28       Impact factor: 4.638

7.  Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.

Authors:  Stephane A Régnier; William Malcolm; Jennifer Haig; Weiguang Xue
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-06

8.  Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.

Authors:  Georgia Kourlaba; John Relakis; Ronan Mahon; Maria Kalogeropoulou; Georgia Pantelopoulou; Olga Kousidou; Nikos Maniadakis
Journal:  Cost Eff Resour Alloc       Date:  2016-04-14

Review 9.  Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.

Authors:  Edith Poku; John Brazier; Jill Carlton; Alberto Ferreira
Journal:  BMC Ophthalmol       Date:  2013-12-04       Impact factor: 2.209

10.  Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.

Authors:  Lindsay Claxton; Bill Malcolm; Matthew Taylor; Jennifer Haig; Claudia Leteneux
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.